Comparative Pharmacology
Head-to-head clinical analysis: EMTRIVA versus TENOFOVIR ALAFENAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRIVA versus TENOFOVIR ALAFENAMIDE.
EMTRIVA vs TENOFOVIR ALAFENAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; emtricitabine is phosphorylated to emtricitabine 5'-triphosphate which competes with deoxycytidine 5'-triphosphate for incorporation into viral DNA, resulting in chain termination.
Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor that, after intracellular conversion to tenofovir diphosphate, inhibits HIV-1 and HBV reverse transcriptase by competing with the natural substrate deoxyadenosine 5'-triphosphate and by DNA chain termination after incorporation into viral DNA.
Emtricitabine 200 mg orally once daily.
25 mg orally once daily with food for HIV-1 infection; 25 mg orally once daily for chronic hepatitis B.
None Documented
None Documented
Terminal elimination half-life ~10 hours (mean 10 h, range 7-14 h) in adults; prolonged in renal impairment (up to 90 h in severe impairment)
Terminal elimination half-life: 0.51 hours for tenofovir alafenamide, but active metabolite tenofovir diphosphate has intracellular half-life ~150–180 hours in PBMCs, supporting once-daily dosing.
Renal excretion of unchanged drug (~86%) by glomerular filtration and active tubular secretion; fecal excretion (<1%)
Renal elimination: ~70% unchanged via glomerular filtration and active tubular secretion; fecal: 2–5%; biliary: <1%.
Category C
Category A/B
Antiretroviral, NRTI
NRTI